一级婬片试看120分钟,安徽少妇BBBB搡BBBB,波多野结衣一级片

香蕉91成人一区二区三区飘花,91精品人妻一区二区三区蜜桃,四川少妇BBw搡BBBB槡BBBB,国产成人91一区二区三区APP

<tr id="cc0cc"></tr>

<nav id="cc0cc"></nav><small id="cc0cc"></small>

<sup id="cc0cc"></sup>

CN

CN EN

Latest News

Latest News Media Downloads Video Center

Kexing Biopharm's clinical trial application accepted for human interferon α1b inhalation solution
2022-08-19

2022-08-19

On the evening of August 18, 2022, Kexing Biopharm...
Kexing Biopharm's clinical trial application accepted for another dosage form of human interferon α2b
2022-08-15

2022-08-15

On the evening of August 14, 2022, Kexing Biopharm Co., Ltd. (hereinafter referred to as "the Company" or "Kexing Biopharm") announced that it had recently received the Notice of Acceptance, an administrative license document issued by the National Medical Products Administration (hereinafter referred to as "NMPA"), indicating that its clinical trial application for "Human Interferon α2b Spray" was accepted.
Kexing Biopharm's clinical trial application accepted for "Pegylated Human Granulocyte Colony-stimulating Factor Injection"
2022-08-02

2022-08-02

On the evening of August 1, 2022, Kexing Biopharm Co., Ltd. (hereinafter referred to as "the Company" or "Kexing Biopharm") announced that it had just received the Notice of Acceptance, an administrative license document issued by the National Medical Products Administration (hereinafter referred to as "NMPA"), indicating that its clinical trial application for "Pegylated Human Granulocyte Colony-stimulating Factor Injection" was accepted.
Kexing Biopharm's conference for reviewing operation and management in first half of 2022and planning key tasks for the second half-year held successfully
2022-08-01

2022-08-01

In the face of the complicated political and economic environment in China and overseas as well as the tough situation in the pharmaceutical industry, Kexing Biopharm proposed the working policy themed as "intensely licensing in new products, firmly promoting R&D and innovation, and proactively creating business in new industries" at the beginning of the year, and continuously followed and implemented the policy in the first half-year.
Phase I clinical trial kick-off meeting of Kexing Biopharm's COVID-19 oral drug SHEN26 Capsule held successfully
2022-07-22

2022-07-22

On July 20, 2022, the phase I clinical trial kick-off meeting of SHEN26 Capsule, a small-molecule oral drug against COVID-19 jointly developed by Shenzhen Kexing Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Kexing Biopharm (688136.SH), and Shenzhen Antiv Pharma Co., Ltd., was successfully held in the Second Affiliated Hospital of Anhui Medical University, indicating the official start of the clinical study for the project.

1 2 3 4 5

Support Hotline

0755-26546500
Online Consultation
QR Code

Scan Code Consultation

91成人在线观看喷欧美国产一区二区亚瑟 | 久久中文字幕一区二区 | 91黄色视频在线免费看 | 色欲av永久无码精品无码蜜桃 | 国产亲妺妺乱A片 | 精品人妻伦一二三区久久 | 国产一区二区三区操逼不卡视频 | 国产精品成AV人在线视午夜片 | 91狠狠色综合久久久夜色撩人 | 麻豆91茄子在线观看 | 国内精品久久久久久久 | 柚子TV成人免费视频网站 | 4444西西大胆无码视频 | 无码人妻丰满熟妇奶水区码 | 国产熟妇毛多 A片欧美蜜臀 | 内射中出日韩无国产剧情 | 美女又色又黄视频 | 电影在线一区二区 | 国产精鲁鲁视频在线观看 | 中文字幕免费观看 | 精品91 海角乱在线观看 | 日本猛少妇BBB欧美一级毛片 | 亚洲一区二区三区在线观看视频 | 激情五月天综合网 | 无码aⅴ一区二区三区 | 亚洲人精品一区二区三区 | 国产黄色片在线免费观看 | 久久久久91精品視頻亞洲一區二區三區 | 国产污污视频在线观看 | 污视频网站在线观看免费 | 国产裸体美女永久免费无遮拦 | 嫩草影院狠狠爱天天 | 日韩国产欧美一区二区 | 日日嗨aV一区二区三区 | 试看120秒一区二区三区 | 姝姝窝人体色www精品 | 麻豆视频在线观看免费 | 特级婬片A片AAA毛片咕噜咕噜 | 81人妻精品无码视频 | 免费无码婬片AAAA片直播色戒 | 国内自拍真实伦在线观看 |

<tfoot id="ccccc"><dd id="ccccc"></dd></tfoot>

<nav id="ccccc"></nav>

<tr id="ccccc"></tr><tr id="ccccc"></tr>

<noscript id="ccccc"><dd id="ccccc"></dd></noscript>